文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

贝达喹啉与德拉马尼治疗耐多药结核的结局比较

Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.
PubMed 文献 · Clin Infect Dis · 2021-01-01

韩国全国性队列研究纳入260例耐多药/利福平耐药结核患者,比较初始选用贝达喹啉或德拉马尼的最终治疗结局。

要点

  • 初始选用贝达喹啉或德拉马尼对耐多药结核最终治疗结局无显著影响。
  • 总体治疗成功率为79.2%,两组不良事件频率无显著差异。
  • 二线注射剂额外耐药11.5%,氟喹诺酮类额外耐药36.2%,两者均耐药14.2%。

核心结论

  • 初始选择贝达喹啉或德拉马尼对耐多药/利福平耐药结核的最终治疗结局及不良事件频率无显著差异。

研究设计与样本

  • 韩国全国性队列研究,纳入2016年9月1日至2018年2月28日获批使用贝达喹啉或德拉马尼的耐多药/利福平耐药结核患者,最终分析260例。

主要发现

  • 260例中贝达喹啉组119例(45.8%),德拉马尼组141例(54.2%)。
  • 30例(11.5%)对二线注射剂额外耐药,94例(36.2%)对氟喹诺酮类额外耐药,37例(14.2%)对两者均耐药。
  • 总体治疗成功率为79.2%。
  • 两组不良事件频率无显著差异。

临床怎么用

  • 在耐多药/利福平耐药结核治疗中,贝达喹啉与德拉马尼均可作为初始选择,疗效与安全性相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 1 September 2016, bedaquiline and delamanid have been administered for the treatment of patients with multidrug-resistant/rifampicin-resistant tuberculosis after the official approval in South Korea. This study aimed to assess and compare the final treatment outcomes of patients who received bedaquiline with those of patients who received delamanid. METHODS: This is a nationwide cohort study of patients with multidrug-resistant/rifampicin-resistant tuberculosis in whom bedaquiline or delamanid was administered from 1 September 2016 to 28 February 2018, after receiving the official approval in South Korea. Patients were classified into the bedaquiline and delamanid group according to the first used drug. We evaluated and compared the final treatment outcomes between the groups. RESULTS: During the study period, 284 patients with multidrug-resistant/rifampicin-resistant tuberculosis were approved to use bedaquiline or delamanid and 260 were included in the final analysis; 119 (45.8%) and 141 patients (54.2%) were classified into bedaquiline and delamanid groups, respectively. Among them, 30 patients (11.5%) exhibited additional resistance to second-line injectable drugs, 94 patients (36.2%) had additional resistance to fluoroquinolones, and 37 patients (14.2%) had resistance to both drugs. The overall treatment success rate was 79.2%. Initiation of bedaquiline rather than delamanid was not associated with treatment success (adjusted odds ratio, .671; 95% confidence interval, .350-1.285). Frequencies of adverse events were not significantly different between the 2 groups. CONCLUSIONS: Initial choice of bedaquiline or delamanid did not make any significant difference in the final treatment outcome or the frequencies of adverse events among patients with multidrug-resistant/rifampicin-resistant tuberculosis.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hwang H, Kang H, Kwon YS, et al. Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid. Clin Infect Dis. 2021. PMID: 33837767. doi:10.1093/cid/ciab304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。